The global cardiotoxicity treatment market size was valued at USD 592.05 Million in 2024 and is expected to reach USD 1021.26 Million by 2032, at a CAGR of 8.10% during the forecast period
The market growth is largely fueled by the increasing prevalence of cardiovascular complications associated with cancer therapies, chemotherapy, and other cardiotoxic drugs, leading to higher demand for early diagnosis, monitoring, and effective treatment interventions
Furthermore, rising awareness among healthcare professionals and patients, advancements in cardioprotective drugs, and the development of targeted therapeutic and monitoring solutions are accelerating the uptake of cardiotoxicity treatment solutions, thereby significantly boosting the industry’s growth